Viral Vectors And Plasmid DNA Manufacturing Market Analysis & Forecast: 2026-2033

Viral Vectors and Plasmid DNA Manufacturing Market Size and Share Analysis - 2026 to 2033

The Viral Vectors and Plasmid DNA Manufacturing Market is anticipated to grow at a CAGR of 23.0% with USD 1,798.6 Mn share in 2026 and is expected to reach USD 7,571.1 Mn in 2033. Rising gene and cell therapy pipelines (According to American Society of Gene & Cell Therapy (ASGCT) as of Q4 2025, 1,888 gene therapy clinical trials were open globally, rising clinical trial activity, increasing GMP manufacturing needs, and advances in vector design and production technologies are driving the growth of the Viral Vectors and Plasmid DNA Manufacturing Market, supported by broader therapeutic applications and expanding commercialization of advanced therapies.

Key Takeaways

• Viral Vector is expected to account the largest share of 68.2% in 2026, driven by their high efficiency, widespread use in approved therapies, and strong presence in clinical pipelines. For instance, in December 2025, according to the data published by National Center for Biotechnology Information, 7 new FDA-approved viral vector-based gene therapies, including 5 AAV-based therapies. Furthermore, according to the data published by the American Society of Gene & Cell Therapy (ASGCT), it has been estimated that 41 gene therapies approved globally as of January 2026 (including genetically modified cell therapies).
• Based on Therapeutic Application, cancer will dominate with 47.5% in 2026, supported by the strong demand for cell & gene therapies, high number of clinical trials, and rising global cancer burden. For instance, in January 2026, according to the data published by the American Cancer Society’s Cancer Statistics 2026 report (published January 2026 and archived on National Center for Biotechnology Information) it has been estimated that about 2.11 Mn new cancer cases and 626,000 cancer deaths are projected in U.S. for 2026.
• Gene therapy holds the dominant share of 46.5% in 2026 on account of high number of approved and pipeline gene therapies, strong reliance on viral vectors (AAV, lentivirus), and significant investment and clinical success rates. For instance, in October 2025, according to the data published by the Precision Medicine Group, LLC., there were about 3,200 active gene therapy clinical studies worldwide as of late 2025, with hundreds of candidates in Phase 1 and Phase 2 and about 35 approaching Phase 3, indicating a significant reliance on viral vector technologies and improving commercialization prospects. (Source: Precision For Medicine)
• North America is expected to acquire the dominant share of 45.0% in 2026, attributed to strong presence of key biotech companies, advanced healthcare and research infrastructure, and favorable regulatory environment. For instance, in January 2026, the U.S. Food and Drug Administration revealed that a more flexible approach to Chemistry, Manufacturing, and Control (CMC) requirements for cell and gene therapies, including viral vector‑based products. The agency's revised policy gives manufacturers greater flexibility in defining product release criteria while upholding quality standards and permits them to make small production adjustments between clinical stages with supporting comparison data. The goal of this regulatory flexibility is to speed up development and lower obstacles to the production of new therapies.

Rising Number of Clinical Trials

Increasing number of clinical trials has significantly driven the viral vectors and plasmid DNA manufacturing market growth. A significant increase in clinical trials for gene therapy and advanced biologics has increased the demand for the viral vectors and plasmid DNA manufacturing. Hece, due to increasing number of clinical trials for new drug discovery there is rise in demand for GMP-grade vectors and plasmids.  For instance, in April 2025, according to the data published by the National Library of Medicine (NLM) reported in April 2025 that since ClinicalTrials.gov's establishment in 2000, over 573,913 clinical studies have been registered. According to ClinicalTrials.gov, 37,597 new studies were uploaded to the registry in 2025 alone, demonstrating a high level of continuous registration activity. According to a different source, more than 7,000 new studies were registered on ClinicalTrials.gov in 2026, maintaining the high yearly trial posting pattern. There have been about 106 new trials registered in 2026 that combine gene therapy (79) and non-genetically modified cell treatment (27).

Source: https://clinicaltrials.gov/about-site/trends-charts

Increasing Government Support and Favorable Regulatory Laws

Favorable government support and regulation have estimated to create significant opportunity for the growth of the viral vectors and plasmid DNA manufacturing market in the near future. Policies promoting biopharma innovation and manufacturing infrastructure has driven the viral vectors and plasmid DNA manufacturing market demand. Increasing regulatory approvals encourage commercialization of the viral vectors and plasmid DNA for drug discovery purpose.

• For instance, on January 2026, the U.S. Food and Drug Administration confirmed a more lenient approach to managing the Chemistry, Manufacturing, and Controls (CMC) regulations for gene and cell treatments. This flexibility is specifically intended to speed up product development and make BLA applications easier, supporting innovation in viral vector-based medicines and associated manufacturing processes.
• Furthermore, in February 2026, the U.S. Food and Drug Administration released draft guidelines that outline a new regulatory framework for producing strong proof of safety and efficacy for customized gene and RNA-based treatments for extremely rare diseases. When tiny patient groups make randomized controlled trials impractical, the "plausible mechanism" paradigm seeks to justify the approval of these tailored treatments. Sponsors are required by the framework to identify a particular genetic, cellular, or molecular aberration that clearly relates to a medical indication. Additionally, sponsors must create a treatment that specifically addresses the underlying or nearby harmful biological changes. According to the proposed guidance, evidence produced using this method may be adequate to justify license or approval under current regulatory processes. In order to prove product safety, efficacy, and quality, the agency stressed the need for adequate nonclinical, clinical, and chemical, manufacturing, and controls (CMC) data.

Expanded Long‑Term Manufacturing Partnerships: A major breakthrough in Viral Vectors and Plasmid DNA Manufacturing

Increasing adoption of inorganic growth strategies like partnership and collaboration has accelerated the manufacturing of plasmid and viral vectors for development of new gene therapies. The growth of gene therapies including those aimed at treating rare and chronic diseases is one of the primary drivers of the viral vectors and plasmid DNA manufacturing market size.

• For instance, in March 2026, Lonza, leading global Contract Development and Manufacturing Organization (CDMO) serving the biotech, nutrition and pharmaceutical markets signed partnership with Genetix Biotherapeutics Inc. (Genetix), a commercial-stage biotechnology company announced the extension of their long-term commercial manufacturing agreement. In order to meet the increasing demand for Genetix's ZYNTEGLO, the only FDA-approved gene therapy for adult and pediatric patients with transfusion-dependent beta-thalassemia, Lonza will increase manufacturing capacity under the expanded agreement.

Source: Lonza

Current Events and Their Impact on the Viral Vectors and Plasmid DNA Manufacturing Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Download Free Sample

Why is Viral Vector Acquiring the Largest Market Share?

Viral vector is projected to account for the largest share of viral vectors and plasmid DNA manufacturing in 2026, representing approximately 68.2% of the total volume. Most commercially approved gene therapies rely on viral vectors (AAV, lentivirus). This directly drives large-scale manufacturing demand. Viral vectors have high transduction efficiency (they deliver genes into cells very effectively). More reliable compared to plasmid DNA and non-viral systems. A large share of ongoing clinical trials in gene and cell therapy use viral vectors. This ensures sustained demand in the near future. Viral vectors are widely used in cell therapies like CAR-T especially lentiviral vectors. These therapies are rapidly expanding in oncology. Viral vector-based products have more regulatory approvals and better-defined GMP manufacturing processes. This gives them a maturity advantage. Viral vectors are complex and high-value products. Even smaller volumes generate higher revenue share compared to plasmid DNA. Increasing funding and collaborations are focused on viral vector production capacity expansion. Many CDMOs specialize in viral vector manufacturing. Growing demand of viral vectors in manufacturing precision and targeted therapies has supported the dominance of segment in the market.

• For instance, in March 2026, SK pharmteco Inc., pharmaceutical company based in U.S. announced to strengthen and increase capabilities throughout its viral vector business, SK Pharmteco is investing USD 100 million. This mostly affects the company's centers of excellence in Corbeil-Essones, France, and King of Prussia, Pennsylvania. Being a flexible CDMO is essential, according to SK Pharmteco, as biopharma businesses create a variety of pipelines that range from established treatments to innovative therapies.

Cancer holds the Largest Market Share

Based on therapeutic application, cancer dominate the market, accounting for a significant 47.5% share in 2026, owing to a significant share of gene therapy clinical trials focused on cancer. Due to more trials focused on developing cancer treatments there is higher demand for vector and plasmid manufacturing. Increasing incidence of cancer worldwide is driving the need for innovative treatments. This boosts investments and product development in oncology. Continuous innovation in immune-oncology and Advancements in gene-modified immune cells and oncolytic viral therapies has supported segment dominance. These approaches rely on viral vectors and plasmid DNA. Cancer research receives significant funding from governments and biotech companies. This accelerates R&D and production needs. For instance, in an effort to accelerate advancements in cancer prevention, detection, and treatment, Worldwide Cancer Research announced financing for 26 fresh, cutting-edge research projects in April 2026. These initiatives are spearheaded by "curestarters" (supporters and researchers) who focus on high-risk, high-reward concepts in an effort to eventually discover cures. They are chosen from applications submitted internationally.

Which End Product segment dominates the market? 

To learn more about this report, Download Free Sample

Gene Therapy account for the largest share of 46.5% in 2026 due to high reliance on viral vectors and plasmid DNA and growing number of approved therapies. Gene therapies directly depend on viral vectors (AAV, lentivirus) for gene delivery. Plasmid DNA is also widely used as a starting material in vector production. Increasing approvals of gene therapies for rare genetic disorders and certain cancers. Commercialization drives large-scale manufacturing demand. A large proportion of ongoing clinical trials are focused on gene therapy which ensures continuous and long-term demand.  
For instance, in 2026, according to the data published by the National Centers for Biotechnology Information, it has been estimated that with more than 3,900 studies and more than 2,150 treatments under development worldwide as of early 2026, the gene therapy industry is rapidly growing. In 2026, the sector will concentrate on handling U.S.FDA holds on advanced studies and filing INDs for in vivo gene therapies (like Siren Biotechnology). AI integration and decentralized trial models are important trends, and the market for cell and gene therapy is expected to expand dramatically by 2035. Furthermore, in March 2026, the U.S. Food and Drug Administration revealed the authorization of the Kresladi (marnetegragene autotemcel), the first gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I). When there is no human leukocyte antigen (HLA)-matched sibling donor available for an allogeneic hematopoietic stem cell transplant, Kresladi is recommended for the treatment of juvenile patients with severe leukocyte adhesion deficit I (LAD-I) caused by biallelic mutations in ITGB2.

Viral Vectors and Plasmid DNA Manufacturing Market Trends

• Rising Focus on AAV and Lentiviral Vectors: Rising focus on AAV and lentiviral vectors has driven the viral vectors and plasmid DNA manufacturing market demand. AAV vectors dominate due to safety and precision. Lentiviral vectors are rapidly growing due to use in CAR-T therapies.

• Growth of Patient-Specific Therapies: Growth of patient-specific therapies, especially in oncology drives need for customized, small-batch manufacturing.

• Expansion of Manufacturing Capacities: Expansion of manufacturing capacities have significantly driven the growth of the market in the near future. Companies are investing in new facilities and modular manufacturing units to meet increasing global demand. For instance, in November 2025, Novartis, a company focused on manufacturing innovative medicines unveiled A new flagship manufacturing hub with end-to-end production capabilities will be established in North Carolina, according to plans. The strategic investment is a significant step toward ensuring that all essential Novartis medications for US patients are produced domestically and distributed to patients nationwide on a large scale.
• This announcement is a component of Novartis' US$23 billion investment over the next five years in U.S.-based infrastructure, which aims to boost production capacity and make it possible for all of the company's major medications to be produced entirely in the U.S. Furthermore, in January 2026, the U.S. Food and Drug Administration (FDA) has approved Siren Biotechnology's first Investigational New Drug (IND) application, allowing the company to begin its first-in-human clinical trial. Siren Biotechnology is a pioneer in Universal AAV Immuno-Gene Therapy for cancer. With this approval, Siren formally becomes a biotechnology company in the clinical stage.

Source: Novartis

• Rising Demand for Personalized Medicine: Rising demand for personalized medicine as driven the viral vectors and plasmid DNA manufacturing market growth. Growth of patient-specific therapies, especially in oncology drives need for customized, small-batch manufacturing. For instance, in April 2026, Stefan Oelrich, President of Bayer AG's Pharmaceuticals Division and a member of the Board of Management, discussed how a persistent emphasis on scientific and business priorities is propelling a predicted growth trajectory towards 2030 on the occasion of Bayer's Pharma Media Day 2026. Furthermore, in 2026, Gilead Sciences, pharmaceutical company expanded its manufacturing of Yescarta, a personalized CAR-T therapy for cancer, by incorporating advanced viral vector technologies at its new facility in Foster City, California. Customized small-batch production is made possible by this facility, which was built to fulfill the growing need for patient-specific medicines.

Source: Bayer

• Integration of End-to-End Manufacturing Solutions: Integration of end-to-end manufacturing solutions has significant opportunity for the growth of the market. Companies are offering full-service platforms from plasmid DNA, viral vectors to final products which improves efficiency and reduces timelines. For instance, in October 2024, Lonza Group AG, manufacturing company, announced a planned expansion of its capabilities to help the biopharmaceutical industry, with an emphasis on cell and gene therapies. The company's capacity to create complicated biologics on a large scale will be improved by the establishment of a new production facility in Geleen, Netherlands. In order to meet the growing need for novel treatments in the healthcare industry, the facility will make use of cutting-edge technologies to optimize production procedures.

Regional Insights

To learn more about this report, Download Free Sample

North America dominates owing to Favorable regulatory environment & Research Infrastructure

North America account 45.0% market share in 2026, supported by favorable regulatory environment and significant funding & investments.  North America is home to major gene therapy developers and vector manufacturers which creates high and consistent demand for viral vectors and plasmid DNA. Advanced healthcare and research infrastructure in North America and well-established biopharma ecosystem, GMP facilities, and research labs enables large-scale and high-quality manufacturing. The North America region (especially U.S.) conducts a large share of global gene therapy clinical trials. Regulatory bodies provide clear guidelines and fast-track approvals for advanced therapies which encourages faster development and commercialization. For instance, in April 2025, Thermo Fisher Scientific Inc., science and clinical research company, unveiled that the company will invest an additional USD 2 billion in the U.S. over next four years, boosting American manufacturing, innovation, and economic competitiveness in the life sciences industry. Thermo Fisher, one of the biggest producers of pharmaceuticals worldwide, makes it possible for biopharmaceutical businesses to create and manufacture their products in the United States. A robust U.S. healthcare supply chain is supported by these new investments in the company's American manufacturing capabilities, which will have a significant multiplier effect throughout the American economy. Over the following four years, the USD 2 billion investment consists of:
USD 1.5 billion in capital expenditures to improve and grow American manufacturing operations
US$500 million in high-impact innovation-focused research and development.

Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Trends

The Asia-Pacific region is poised to be as the fastest-growing region through 2026-2033, owing to rising prevalence of chronic and genetic diseases. Increasing cases of genetic disorders, cancer, and infectious diseases has driven the viral vectors and plasmid DNA manufacturing market demand in the Asia Pacific region. For instance, in 2026, according to the data published by the National Center for Biotechnology Information, over 9.8 million people in Asia are diagnosed with cancer each year, making it the most common disease in the Asia Pacific region. With 49% of all cancer cases worldwide, Asia has the highest cancer burden, highlighting the region's rising workforce and public health issues.

Furthermore, government bodies in Asia Pacific region are promoting biotech through regulatory reforms, funding programs, and national missions (e.g., biopharma initiatives). These policies accelerate manufacturing and innovation.  For instance, in February 2026, according to the data published by the Press Information Bureau, nodal agency of Government of India it has been explained that the India's approach to pharmaceuticals has undergone a significant change with the Union Budget 2026–2027, which places biopharma and biologic medicines at the core of its production and healthcare strategy. This is in line with the Indian government's goal of making India a major player in the global biopharmaceutical industry and gaining 5% of the world market. launch of Biopharma SHAKTI, a committed national project to improve India's end-to-end biologics and biosimilars ecosystem that will cost Rs. 10,000 crores over five years. The initiative's goals are to increase India's competitiveness in international biologics supply chains, lessen reliance on imports, and boost domestic discovery and production of high-value biopharmaceutical goods and medications. Three new National Institutes of Pharmaceutical Education and Research (NIPERs) have been established, and seven existing NIPERs have been upgraded, strengthening and expanding the Biopharma-focused network. This proposal aims to address the increasing need for highly specialized human resources in the manufacturing, research, development, and regulation of biopharmaceuticals.

Advanced Research and Healthcare Infrastructure is accelerating the Viral Vectors and Plasmid DNA Manufacturing Market Demand in United States

The U.S. viral vectors and plasmid DNA manufacturing market is undergoing a period of robust expansion. The U.S. country has leading universities and research centers actively working on molecular biology and gene editing which fuels continuous innovation. Moreover, the country has large number of specialized contract manufacturing organizations which supports outsourcing and scalability. Strong financial support from government agencies in U.S. like NIH, venture capital, and private biotech firms drives innovation and capacity expansion. For instance, in February 2026, the Platform Vector Gene Therapy (PaVe-GT) initiative, which aims to increase the effectiveness of rare-disease gene therapy development by utilizing the same AAV delivery system and manufacturing techniques across multiple programs, was highlighted by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health. Additionally, NCATS claims to be involved in the leadership of the Bespoke Gene Therapy Consortium (BGTC), a public-private collaboration aimed at creating standards and platforms to expedite the creation and distribution of gene therapies. Simultaneously, the U.S. FDA said in January 2026 that its adaptable strategy to chemistry, manufacturing, and control (CMC) regulations for gene and cell therapies has aided in accelerating product development and is anticipated to continue facilitating quicker commercialization. These advancements demonstrate how robust U.S. research institutions, government-sponsored initiatives, and regulatory backing are driving innovation and scale production in plasmid DNA and viral vectors.

China Viral Vectors and Plasmid DNA Manufacturing Market Trends

The China viral vectors and plasmid DNA manufacturing market projected to grow significantly during the upcoming years. China has a fast-growing biotech and pharmaceutical sector. Increasing number of companies involved in gene therapy and vector production. Rapid growth of Contract Development and Manufacturing Organizations - CDMOs strengthens the supply chain and production capabilities. Moreover, China has lower operational and labor costs compared to Western countries which attracts both international and domestic outsourcing. For instance, in March 2026, AstraZeneca plc, pharmaceutical company, unveiled a USD 15 billion investment plan in China through 2030 to increase its capacity for production, research, and development there. This strategy includes building a cell therapy manufacturing and supply base and innovation center in Shanghai. This facility will boost China's biotech supply chain and local manufacturing capability for complicated biologics and gene-based treatments by supporting the production of cutting-edge therapeutic products including CAR-T cell therapies.

Who are the Major Companies in Viral Vectors and Plasmid DNA Manufacturing Market

Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.

Key News

• In April 2026, Virica Biotech ("Virica"), a cell enhancer company that specializes in Viral Sensitizers (VSE) for the production of viral vectors, announced that it has received funding and advisory services from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) under the Canada–Japan Corporate Co-Innovation Program for a partnership with FUJIFILM Biosciences. In order to assist academic and commercial AAV manufacturers worldwide, the partnership will concentrate on refining a VSE formulation for FUJIFILM Biosciences BalanCD HEK293 medium.
• In March 2026, New England Biolabs, Inc., life sciences company signed collaboration with Touchlight, biotechnology company based in U.K., to innovate and launch the EnClose Cell-free dbDNA Synthesis Kit. This innovative kit allows for the benchtop enzymatic synthesis of Touchlight's exclusive doggyboneTM DNA (dbDNA), a linear, covalently closed, double-stranded DNA that offers researchers a quick, cell-free substitute for conventional plasmid DNA in the creation of a variety of nucleic acid treatments.
• In February 2025, Novartis AG, innovative medicines company, as part of a larger plan to improve cell and gene therapy capabilities throughout Europe, Novartis has formally established a €40 million (US$41.2 million) viral vector production plant in Mengeš, Slovenia. The facility, called VIFA One, is the company's initial attempt at producing viral vectors on the continent.
  The building of VIFA Novartis has positioned the plant as a state-of-the-art, completely automated site since one started in 2023. In order to increase productivity in the manufacture of viral vectors, robotics will supervise every step of the process in a single location. With this growth, Novartis now has €3.5 billion (US$3.6 billion) invested in Slovenia.

Market Report Scope 

Analyst Opinion

• The market outlook remains strong, but value creation will increasingly depend on manufacturing reliability rather than only scientific innovation. FDA continues to expand its cell and gene therapy guidance framework, including guidance on manufacturing changes, comparability, potency assurance, and small-population trial design, which indicates that regulatory expectations for consistency and control are rising. As a result, the companies most likely to benefit are those that can offer integrated development-to-commercial manufacturing support with strong CMC, analytical, and scale-up capabilities.
• The Viral Vectors and Plasmid DNA Market is being driven by structural therapeutic demand rather than short-term hype. By Q4 2025, 41 gene therapies had already been approved globally, and 1,888 gene therapy clinical trials were open, which shows that demand for viral vectors and plasmid DNA is being sustained by a deep clinical and commercial pipeline across rare diseases, oncology, and other high-value indications.
• Plasmid DNA is no longer just a supporting raw material; it has become a strategic manufacturing backbone for the market. FDA guidance explicitly notes that DNA plasmid intermediates are used in the manufacture of gene therapy products such as AAV or lentiviral vectors, while industry guidance work has also focused on plasmids as a critical starting material for cell and gene therapy production. This means suppliers with strong plasmid quality systems, release specifications, and scalable GMP capacity are likely to gain a stronger competitive edge.

Market Segmentation

• By Product Type
  • Viral Vector
    • Retroviral Vectors
    • Adenoviral Vectors
    • Lentiviral Vectors
    • Adeno-associated Viral Vectors
    • Others
  • Plasma DNA
  • Non-viral DNA Vectors
• By Therapeutic Application
  • Cancer
  • Inherited Disorders
  • Vitrectomy Surgery Devices
  • Infectious Diseases
  • Others
• By End Product
  • DNA Vaccines
  • Gene Therapy
  • Immunotherapy
  • Others
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Interviews with gene therapy researchers and clinicians to explore challenges in viral vector delivery and therapeutic applications.
• Insights from viral vector manufacturers and CDMO representatives on production advancements and scalability.
• Discussions with regulatory affairs professionals on the impact of guidelines and policy changes on market growth.
• Conversations with biotech investors and executives on investment trends and future market outlook.
• Interviews with plasmid DNA manufacturers to understand production challenges, cost, and logistics.
• Discussions with academic researchers on the role of viral vectors and plasmid DNA in gene therapy, vaccines, and personalized medicine.

Databases

• ClinicalTrials.gov
• PubMed
• EMBL-EBI
• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• Organisation for Economic Co-operation and Development (OECD)

Magazines

• Pharmaceutical Technology
• Nature Biotechnology
• Genetic Engineering & Biotechnology News (GEN)
• BioTechniques

Journals

• Journal of Gene Medicine
• Trends in Biotechnology
• Molecular Therapy
• Gene Therapy
• Human Gene Therapy

Newspapers

• The Wall Street Journal
• Financial Times
• The New York Times
• The Guardian

Associations

• European Society of Gene & Cell Therapy (ESGCT)
• American Association of Pharmaceutical Scientists (AAPS)
• American Society of Gene & Cell Therapy (ASGCT)
• International Society for Cell & Gene Therapy (ISCT)

Public Domain Sources

• U.S. Food and Drug Administration (FDA) Resources
• European Medicines Agency (EMA) Resources
• Company Annual Reports and Investor Presentations
• Government Health Ministry Publications
• Clinical Trial Registries such as ClinicalTrials.gov

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years